Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/61020
Authors: 
Lichtenberg, Frank
Pettersson, Billie
Year of Publication: 
2012
Series/Report no.: 
CESifo Working Paper: Social Protection 3894
Abstract: 
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by 0.60 years during the period. The estimates indicate that longevity depends on the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital utilization in Sweden, so the cost per life-year gained from the introduction of new drugs was quite low.
Subjects: 
longevity
pharmaceutical
innovation
drugs
Sweden
JEL: 
I12
J11
L65
O33
Document Type: 
Working Paper

Files in This Item:
File
Size
355.87 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.